GameStop Corp. vs Oruka Therapeutics Inc. Common Stock — how do they compare? GameStop Corp. trades at $26.61 (market cap $13.70B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: GameStop Corp. is far larger — about 2.7× Oruka Therapeutics Inc. Common Stock's market cap, and GameStop Corp. is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| GME | ORKA | |
|---|---|---|
Market Cap | $13.70B | $5.08B |
Volume | 16,349,771 | 685,276 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.23 | $113.08 |
52-Week Low | $17.87 | $26.19 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $12.97B | $4.21B |
Signals from Pluang's Aura AI — not financial advice
GME trades at $27.22, down slightly by 0.04% on the day. The stock shows strong technical momentum with bullish moving averages and positive price action near resistance at $28. Fundamentally, the company reported net income of $131.3 million in 2025 with improving profit margins of 25.16%, though revenue declined to $3.82 billion. Recent insider buying by CEO Ryan Cohen and directors has driven positive sentiment, with multiple purchases totaling over $26 million in September 2026.
GME presents a mixed outlook with strong insider confidence but challenging fundamentals. The investment opportunity lies in continued operational turnaround and potential strategic moves, while risks include revenue declines, competitive pressures in retail gaming, and the stock's meme stock volatility. Analyst consensus remains cautious with only 16.7% buy ratings versus 27.8% sells.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →